Zelira Therapeutics Limited (ASX:ZLD)

Market Cap	4.05M
Revenue (ttm)	656.00
Net Income (ttm)	-3.63M
Shares Out	11.90M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	403
Average Volume	2,929
Open	0.3400
Previous Close	0.3500
Day's Range	0.3400 - 0.3400
52-Week Range	0.3100 - 0.6950
Beta	0.49
RSI	47.09
Earnings Date	Nov 26, 2025

About Zelira Therapeutics

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment product...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ZLD

Financial Performance

In 2025, Zelira Therapeutics's revenue was 656, a decrease of -99.31% compared to the previous year's 94,952. Losses were -3.63 million, -90.08% less than in 2024.